Navigation Links
VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells

Researchers at the Virginia Commonwealth University Massey Cancer Center have found a new signaling component that influences movement of human breast cancer cells toward epidermal growth factor.

In the August issue of the Journal of Biological Chemistry, researchers showed that epidermal growth factor, which plays a critical role in breast cancer progression, stimulates sphingosine kinases - SphK1 and SphK2 - a family of enzymes that forms the potent lipid mediator, sphingosine-1-phosphate, and that breast cancer cells are unable to move without these kinases.

"If we understood how tumor cells spread or metastasize, we would be able to design better tools to help treat cancers," said lead author Sarah Spiegel, Ph.D., chair and professor in the VCU Department of Biochemistry and co-leader of the Massey Cancer Center Cell Signaling program.

Spiegel, who is internationally recognized for her pioneering work on new lipid mediators that regulate cell growth and cell death, and her colleagues, first discovered the role of sphingosine-1-phosphate in cell growth regulation nearly a decade ago. While researchers know that SphK1 is stimulated by multiple growth factors, less is known about how SphK2 is regulated. Spiegel and her team are continuing this work to better understand the functions of these enzymes.

"Our work suggests that sphingosine kinases are potential new targets in cancer therapy," she said.


'"/>

Source:Virginia Commonwealth University


Page: 1

Related biology news :

1. Massey Cancer Center researcher helps to identify a piece of the cancer puzzle
2. VCU Massey Cancer Center researchers identify a new class of anti-cancer drugs based on platinum
3. Massey researchers induce cell death in leukemia
4. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
5. Jump-starting T Cells In Skin Cancer
6. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
7. Fox Chase Cancer Center scientists identify immune-system mutation
8. Breakthrough Microarray-based Technology for the Study of Cancer
9. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
10. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
11. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... to bring innovative medical technologies, services and solutions to the healthcare market. The ... implementation of various distribution, manufacturing, sales and marketing strategies that are necessary to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: